Pharm-Olam's response to COVID-19 from CEO Rob Davie, PhD. Read Here
Comprehensive risk-based monitoring (RBM) strategies and technology are vital to the success of your clinical trial. We also support your study by making sure your strategy meet RBM functional requirements as outlined in part two of TransCelerate Biopharma’s RBM Technology Considerations. Our cross-functional teams evaluate your study protocol to further identify risks using our Risk Assessment Categorization Tool (RACT), and integration into Pharm-Olam's leading bow tie risk management system.
A holistic, end-to-end RBM strategy needs the right technology to support it. Pharm-Olam leverages Medidata's Rave Clinical Cloud to power our clinical execution and RBM strategies. Medidata's Rave Clinical Cloud leads the industry, it captures data from a all study data sources such as EDC, eDiaries, central laboratories, imaging documents and brings it into one unified platform for data aggregation and analysis.
From start to close, our clinical operations team works with you to ensure the RBM strategy for your study is fully able to identify and manage risks and provide the highest data integrity. To learn more about how Pharm-Olam is Powered by Medidata, click link below.
Pharm-Olam's Global Site Activation Unit (GSAU), maintains a team dedicated to guiding expeditious clinical trial site activation. With global start-up leads and local teams, the GSAU team provides the following:
To learn more about our Global Site Activation Unit and their services, click the button below.
Having a large global reach across more than 60+ countries around the world means that your study receives the customized geographical support it needs. Our scalable delivery ecosystem includes a vast network of personnel, sites, partners and three Centers of Excellence. This gives your study the advantage of having the right people in the right locations to provide the specialized knowledge and solutions to manage your study successfully.
In addition to our Centers of Excellence, Pharm-Olam offers our Expeditionary CRO service model to extend the reach of your study even further by providing access to remote or developing countries and regions (Africa, South America and Asia Pacific).
Pharm-Olam as part of our scalable delivery ecosystem can also provide a functional service provider (FSP) solution for CRA coverage to ensure all your monitoring needs are met.
Pharm-Olam’s Culture of Accountability, another key element within our Pattern of Excellence, means that you can count on our teams to take ownership for their work and that of the sites and vendors involved in your clinical trial. Because our CRAs are empowered to make decisions and provide solutions, your study is positioned for success.
When a site falls behind in enrollment or a vendor suffers a issue, we do not point fingers. We work together, side-by-side, to resolve the situation with our Sponsor and the involved parties. Clinical Trials are like an ecosystem and it takes a team approach to make them thrive.
By taking ownership and responsibility for the success of your study, we deliver on our promise to demonstrate our pattern of excellence in every service we provide.
To learn more about our Pattern of Excellence, visit our Why Pharm-Olam page.